Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Plecanatide (Trulance) vs Teduglutide (Gattex)
An educational, source-based comparison of Plecanatide (Trulance) and Teduglutide (Gattex) — how each peptide works, what it's researched for, and what to know before going deeper.
Synthetic analog of human uroguanylin that activates guanylate cyclase-C in a pH-dependent manner, increasing intestinal fluid secretion and transit.
- Chronic idiopathic constipation
- IBS-C
- • FDA-approved.
- • Diarrhea most common adverse event.
GLP-2 analog for short bowel syndrome dependent on parenteral support.
Recombinant analog of glucagon-like peptide-2 with alanine→glycine substitution at position 2, resisting DPP-IV degradation; promotes intestinal mucosal growth, villus height, and absorptive capacity.
- Short bowel syndrome with intestinal failure
- Reduction of parenteral nutrition dependence
- • FDA-approved.
- • Colorectal polyp surveillance required.
- • Risk of intestinal obstruction and biliary/pancreatic disease.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Plecanatide (Trulance) | Plecanatide phase 3 | American Journal of Gastroenterology | 2017 | Significantly improved complete spontaneous bowel movements vs placebo. |
| Teduglutide (Gattex) | STEPS trial | Gastroenterology | 2012 | Reduced parenteral support volume in SBS patients vs placebo. |
Side-effect & safety grid
- FDA-approved.
- Diarrhea most common adverse event.
- FDA-approved.
- Colorectal polyp surveillance required.
- Risk of intestinal obstruction and biliary/pancreatic disease.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Plecanatide (Trulance) vs Teduglutide (Gattex) — Key differences
- Class: Plecanatide (Trulance) is classified as GC-C Agonist · Gastrointestinal, while Teduglutide (Gattex) is GLP-2 Analog · Gastrointestinal.
- Primary research focus: Plecanatide (Trulance) — chronic idiopathic constipation; Teduglutide (Gattex) — short bowel syndrome with intestinal failure.
- Tag: FDA-Approved · GI vs FDA-Approved · GI.